CliffBio
small molecule

VEMLIDY

TENOFOVIR ALAFENAMIDE FUMARATE

Loss of exclusivityFebruary 2033latest FDA-listed patent expiry
CompanyGilead Sciences →See this company's full patent-cliff portfolio

Drug detail

Brand nameVEMLIDY
Active ingredientTENOFOVIR ALAFENAMIDE FUMARATE
StrengthEQ 25MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalNovember 2016
Marketing statusRX

Listed patents

PatentExpiresType
9296769*PEDFebruary 2033—
8754065*PEDFebruary 2033—
8754065August 2032substance, product
9296769August 2032substance, product

Regulatory exclusivity

CodeExpires
NPPMarch 2027

More from Gilead Sciences

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.